Peptide questions · Pramlintide

Pramlintide side effects: what studies and users report

Reviewed Evidence: EstablishedPublished by PepVault

The side effects most commonly reported for pramlintide are nausea, loss of appetite and vomiting, among 7 the library lists; the library’s evidence on it includes controlled trials in people.

Its safety note opens: The Symlin label carries a boxed warning: taken with insulin, which is how it is approved, it raises the risk of severe low blood sugar, mostly in type 1 diabetes, usually within 3 hours of a dose; pramlintide alone does not cause low blood sugar.

What is commonly reported with pramlintide

  • Nausea
  • Loss of appetite
  • Vomiting
  • Headache
  • Fatigue
  • Dizziness
  • Low blood sugar (with insulin)

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other metabolic & GLP-1 compounds the library lists it for
EffectAlso listed for (of 24)
Nausea21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more
Loss of appetiteNone: listed for Pramlintide alone
Vomiting18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more
Headache3: Exenatide, Setmelanotide, Orforglipron
Fatigue7: Semaglutide, Tirzepatide, Retatrutide, Dulaglutide and 3 more
Dizziness2: Exenatide, Mazdutide
Low blood sugar (with insulin)1: Exenatide
A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Track pramlintide in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which pramlintide side effects the metabolic & GLP-1 group shares

Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Pramlintide shares 6 of its 7 listed effects with at least one other metabolic & GLP-1 compound; loss of appetite is listed for pramlintide alone.

What the pramlintide safety notes say

The library’s safety note

The Symlin label carries a boxed warning: taken with insulin, which is how it is approved, it raises the risk of severe low blood sugar, mostly in type 1 diabetes, usually within 3 hours of a dose; pramlintide alone does not cause low blood sugar. That is why mealtime insulin is cut by half at the start, glucose is checked often, and the label rules it out for people who can't feel their lows, have gastroparesis, an HbA1c above 9% or recurrent severe lows. A low while driving or operating machinery can cause serious injury. Nausea is the most common side effect, highest at the start and fading in most people. A pen is never shared, even with a new needle. These are label findings; review them with your clinician.

The library’s interaction note

Pramlintide is never mixed with insulin in one syringe: it changes how both are absorbed, so they are separate shots at separate sites. It slows stomach emptying, so the label suggests taking oral medicines whose quick onset matters (pain relievers, antibiotics, oral contraceptives) at least 1 hour before or 2 hours after it, and it is not recommended with drugs that change gut motility. Other glucose-lowering drugs may need insulin adjustments. Discuss all your medicines with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the pramlintide reports come from

The library rates the evidence on pramlintide as established: clinical trials or FDA-approved use exist.

Of the library’s 6 research notes on pramlintide, 4 rest on randomized trials and 2 on clinical data.

Our 8 study pages on pramlintide: 6 randomized trials, 1 clinical trial and 1 meta-analysis.

So pramlintide has controlled trials in people to set its listed effects against.

What our pramlintide study pages report on safety

Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose group

Randomized trial, human, 2023: Body weight fell by 0.8 kg in the low-dose group and 1.6 kg in the high-dose group, while low blood sugar events were a little more common with ADO09 (142 vs. 115 and 96 vs. 79), and gut side effects were more frequent but mostly passed. Putting pramlintide and insulin in one mealtime shot improved short-term glucose control and weight compared with aspart, with slightly more low blood sugar events and gut side effects.

Pramlintide pump infusion: HbA1c fell 0.35% in 16-week pilot

Clinical trial, human, 2009: Every patient had mild low blood sugar after meals but none had severe episodes, and 3 of the 11 had mild nausea early on.

Pramlintide: weight loss maintained over 12 months in obesity

Randomized trial, human, 2008: Nausea was the most common side effect in the first 4 months (9-29% on pramlintide vs. 2% on placebo), was mostly mild to moderate, and affected under 10% of people during the extension. In this trial, adding pramlintide to a lifestyle program helped people with obesity lose more weight than placebo and keep it off for a year at two of the dosing schedules, with nausea as the main early side effect.

Pramlintide: 3.7% placebo-corrected weight loss at 16 weeks

Randomized trial, human, 2007: The most common side effect was mild nausea that passed, and weight loss was similar in people with nausea (3.9 ± 0.5%) and without it (3.6 ± 0.5%). In this short trial, pramlintide alone, without a lifestyle program, led to modest weight loss beyond placebo in people with obesity, and the loss did not depend on having nausea.

Questions people ask

What are the side effects of pramlintide?

The side effects most commonly reported for pramlintide are nausea, loss of appetite and vomiting, among 7 the library lists; the library’s evidence on it includes controlled trials in people.

Do pramlintide’s side effects come from human studies?

The library rates the evidence on pramlintide as established, and the library’s evidence on it includes controlled trials in people.

Which pramlintide side effects are its own?

Among the metabolic & GLP-1 compounds, the library lists loss of appetite for pramlintide alone.

Does pramlintide interact with other medicines?

The library’s interaction note on pramlintide begins: pramlintide is never mixed with insulin in one syringe: it changes how both are absorbed, so they are separate shots at separate sites.

More on pramlintide

Track it in the app

PepVault for iPhone

Track pramlintide in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo